Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

WHA

- PMLiVE

Countries hail ‘landmark’ drug pricing transparency resolution, despite watering down

US among those in favour of price transparency

- PMLiVE

Huntsworth bolsters market access capabilities with Creativ-Ceutical

Adds new capabilities and global presence

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Tit for tat as PBMs blame pharma for high drug prices

US Senate turns its spotlight on 'middlemen'

- PMLiVE

Gottlieb signs off with flair – and pledge of further drug price commentary

Highlights issues of insulin prices and competition

- PMLiVE

Trump budget targets rebates, out-of-pocket costs

Biotech sector welcomes end to rebates, but worries about Medicare cuts

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

- PMLiVE

Senate grilling makes pharma CEOs squirm, but give little ground

Some signal willingness to compromise, but oppose most radical reforms

- PMLiVE

Fireworks likely at Senate drug pricing hearing today

Senators fire broadsides: "I hope CEOs don't blame everyone but themselves"

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

- PMLiVE

CEOs agree to Congressional grilling on US drug prices

Tough questions await pharma bosses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links